Sponsor hub
Genentech, Inc. clinical trial failures
Review 45 stopped clinical trials from Genentech, Inc., including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 6 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OTHER/UNKNOWN
- 24
- OPERATIONAL
- 15
- EFFICACY/FUTILITY
- 5
- SAFETY
- 1
Notable sponsors
- Genentech, Inc.
- 45
Related phases
- Phase II
- 21
- Phase I
- 10
- Phase III
- 10
- Phase IV
- 4
Crawlable stopped-trial records
Open ExploreShowing up to 45 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase II Acute Kidney Injury trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Unlikely to demonstrate a statistically significant clinical benefit
Phase II Ulcerative Colitis trial by Genentech, Inc.. Stop reason: EFFICACY/FUTILITY.
Based on a futility analysis, which suggested that the Moonglow study was unlikely to meet its primary endpoint.
Phase II Idiopathic Pulmonary Fibrosis trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Sponsor decided to discontinue the study after review of clinical data by the iDMC. This decision was based on unblinded evaluation of clinical efficacy which showed a trend towards futility \& was not related to any safety concerns of vixarelimab.
Phase I Solid Tumour trial by Genentech, Inc.. Stop reason: SAFETY.
Following a thorough review of safety data, preliminary efficacy data and an evaluation of overall risk-benefit, Sponsor made the decision to end the study.
Phase II Chronic Obstructive Pulmonary Disease trial by Genentech, Inc.. Stop reason: OPERATIONAL.
The study was terminated by Sponsor due to patient recruitment challenges.
Phase I Refractory Cancer trial by Genentech, Inc.. Stop reason: OPERATIONAL.
GO44669 study has been withdrawn due to an internal Sponsor decision. The decision was not due to any safety or efficacy concerns with the study drug.
Phase I Solid Cancers trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.
Phase II Non-alcoholic Steatohepatitis trial by Genentech, Inc.. Stop reason: OPERATIONAL.
The study was terminated due to strategic business reasons.
Phase II Macular Degeneration, Age-Related trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).
Phase II Macular Degeneration, Age-Related trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).
Phase II Ulcerative Colitis trial by Genentech, Inc.. Stop reason: EFFICACY/FUTILITY.
This study was terminated early by the Sponsor based on the interim analysis of Study GA39925 (NCT03558152) that showed low efficacy of UTTR1147A in ulcerative colitis. Development of the drug in this indication has been terminated.
Phase I Multiple Myeloma trial by Genentech, Inc.. Stop reason: OPERATIONAL.
Slow recruitment
Phase II Chondrosarcoma trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Efficacy not evident in this population.
Phase II Chronic Spontaneous Urticaria trial by Genentech, Inc.. Stop reason: OPERATIONAL.
Development of MTPS9579A was terminated for strategic/business reasons.
Phase II Alzheimer's Disease trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Study was terminated during Open Label Extension period because analyses of placebo-controlled Blinded portion of study did not show any evidence of clinical efficacy or modulation of accumulation of tau PET signal at any of the doses studied.
Phase IV Moderate-to-severe Allergic Asthma trial by Genentech, Inc.. Stop reason: OPERATIONAL.
Due to low enrollment, this study was terminated early.
Phase I Breast Cancer trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
The Sponsor decided to halt the development of GDC-0810, but not due to any safety concerns.
Phase II Breast Cancer trial by Genentech, Inc.. Stop reason: OPERATIONAL.
The Sponsor decided to halt the development of GDC-0810, but not due to any safety concerns.
Phase IV Hemophilia A trial by Genentech, Inc.. Stop reason: OPERATIONAL.
The Sponsor decided to terminate the study early for several reasons (low enrollment, limited variety of surgery types, and available scientific data).
Phase III Lupus Nephritis trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.
Phase II Lupus Erythematosus, Systemic trial by Genentech, Inc.. Stop reason: EFFICACY/FUTILITY.
The study was ended early due to the lack of efficacy seen in the parent study GA30044.
Phase III Rheumatoid Arthritis trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
Phase III Rheumatoid Arthritis trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
Phase II Rheumatoid Arthritis trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
Phase III Rheumatoid Arthritis trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
Phase II Urticaria trial by Genentech, Inc.. Stop reason: OPERATIONAL.
Recruitment was stopped after an interim analysis of the parent GS39684 study.
Phase III Systemic Lupus Erythematosus trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.
Phase I Healthy Volunteers trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Molecule development was terminated
Phase II Geographic Atrophy trial by Genentech, Inc.. Stop reason: EFFICACY/FUTILITY.
The study was terminated early by the Sponsor due to lack of efficacy.
Phase III Rheumatoid Arthritis trial by Genentech, Inc.. Stop reason: OPERATIONAL.
Recruitment was fully completed for this study; however, the study was terminated during conduct after the primary endpoint analysis was completed.
Phase II Urothelial Carcinoma trial by Genentech, Inc.. Stop reason: OPERATIONAL.
The study was prematurely terminated due to slow patient accrual and discontinuation of clinical development of MOXR0916 due to Sponsor's strategic priorities.
Phase III Stroke trial by Genentech, Inc.. Stop reason: OPERATIONAL.
The study was terminated due to slow enrollment.
Phase I Healthy Volunteer trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
The molecule (GDC-276) is no longer in development.
Phase II Ovarian Cancer trial by Genentech, Inc.. Stop reason: EFFICACY/FUTILITY.
The primary objective of PFS did not meet pre-specified criteria.
Phase III Lupus Erythematosus, Systemic trial by Genentech, Inc.. Stop reason: OPERATIONAL.
During a safety review of studies U2970g and U2971g, the Data Monitoring Committee recommended that enrollment in this extension trial be terminated.
Phase I Chronic Lymphocytic Leukemia trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Kidney Transplantation trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Solid Cancers trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
The study was terminated early by the Sponsor for reasons unrelated to patient safety or anti-tumor activity.
Phase II Malignant Melanoma trial by Genentech, Inc.. Stop reason: OPERATIONAL.
Recruitment challenges
Phase IV Cystic Fibrosis trial by Genentech, Inc.. Stop reason: OPERATIONAL.
This study was terminated for administrative reasons. There were no safety concerns.
Phase III Lupus Nephritis trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase IV Cystic Fibrosis trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
Most patients were unable to perform the test being used to measure lung function, thus it became clear the study would not yield clinically meaningful data
Phase I Solid Tumors trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
A recommended Phase 2 dose and schedule was not identified and the study was terminated before initiation of Stage 2B.
Phase II Diffuse Large B-Cell Lymphoma trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
The NAVIGATE study has been terminated due to non-safety related reasons.
Phase III Renal Cell Cancer trial by Genentech, Inc.. Stop reason: OTHER/UNKNOWN.
No patients were enrolled, study cancelled before start